The Asurys system is the latest addition to Boston Scientific’s StoneSmart Solutions product ecosystem.

Increasing prevalence of bleeding disorders, rising number of surgical procedures, aging population, and growing focus on ...

The deal positions Boston Scientific to compete with Medtronic for a market that analysts believe is highly under-penetrated.

Boston Scientific (NYSE:BSX) announced positive data from a randomized clinical trial evaluating its EKOS endovascular system.

Boston Scientific (NYSE:BSX) announced today that it received FDA 510(k) clearance for its Asurys fluid management system.

Boston Scientific has declined over 35% in six months, yet maintains double-digit growth and 28% operating margins, creating a compelling buy opportunity. BSX trades at mid-tier valuations, despite a ...

NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Boston Scientific Corporation (NYSE: BSX) to contact the firm. Those who purchased BSX securities between ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Boston Scientific Corporation (NYSE: BSX) securities of a pending securities class action. THE CASE: A class action ...

In 1992, an episode of the iconic TV show Law & Order aired a storyline that now feels eerily prescient. The episode revolved around a teenage boy who dies due to a faulty pacemaker. As detectives dig ...

Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond James downgraded the stock.

Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endova ...